Furthermore, identification of microglial cytoprotective pathways for entities such as EPO and Wnt1 [59-61] may synergistically enhance the development of treatments for Alzheimer's disease. This evidence concerns the gene EPO and early-onset autosomal dominant Alzheimer disease.